Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen LaboratoriesNSE:MOREPENLAB -3.17%76 EV-to-EBITDA is 19.28 as of Jul. 17, 2026, which is 28% above its 10-year median of 15.08. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 76/100 and a GF Value™ of ₹49.98 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 741 Drug Manufacturers companies, Morepen Laboratories ranks worse than 66.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Morepen Laboratories's enterprise value is ₹33,310 Mil.
Morepen Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,728 Mil. Therefore, Morepen Laboratories's EV-to-EBITDA for today is 19.28.
The historical rank and industry rank for Morepen Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:MOREPENLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1 Med: 15.08 Max: 75.03
Current: 19.28
During the past 13 years, the highest EV-to-EBITDA of Morepen Laboratories was 75.03. The lowest was 5.10. And the median was 15.08.
NSE:MOREPENLAB's EV-to-EBITDA is ranked worse than 66.67% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs NSE:MOREPENLAB: 19.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Morepen Laboratories's PE Ratio (TTM) for today is calculated as:
Morepen Laboratories's share price for today is ₹58.90.
Morepen Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Morepen Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's EV-to-EBITDA falls into.
Morepen Laboratories's current Enterprise Value is ₹33,310 Mil.
Morepen Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,728 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a EV-to-EBITDA of 19.28 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Morepen Laboratories. This is 28% above median its historical median of 15.08. Over the past decade, Morepen Laboratories' EV-to-EBITDA has ranged from 5.10 to 75.03. According to the industry distribution chart, Morepen Laboratories ranks #494 out of 741 companies in the Drug Manufacturers industry, placing it in the top 66.7%.
Is Morepen Laboratories' EV-to-EBITDA too high?
Morepen Laboratories' current EV-to-EBITDA of 19.28 is 28% above median its 10-year median of 15.08. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 75.03. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Morepen Laboratories' value of 19.28 is 48% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #494 out of 741 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #494 out of 741 companies for EV-to-EBITDA. This places Morepen Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. Morepen Laboratories' value of 19.28 is 48% above this benchmark. Historically, Morepen Laboratories' own EV-to-EBITDA has ranged from 5.10 to 75.03 over the past decade. While the company's 10-year median is 15.08 vs. the industry median of 13.03, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current EV-to-EBITDA of 19.28 is 48% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Morepen Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current EV-to-EBITDA is 19.28, which is 28% above median its own 10-year median of 15.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.98, compared to a current price of ₹58.90 — trading 17.8% above its estimated fair value. The current EV-to-EBITDA is 19.28, which is 28% above median its 10-year median of 15.08 and 48% above the Drug Manufacturers industry median of 13.03. Morepen Laboratories' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current EV-to-EBITDA is 19.28 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹58.90 is trading 17.8% above its estimated GF Value™ of ₹49.98.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
EV-to-EBITDA: 19.28 (28% above median its 10-year median of 15.08)
GF Value™: ₹49.98 vs. price of ₹58.90 (17.8% above fair value)
Industry Position: 48% above the Drug Manufacturers median (#494 of 741)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:MOREPENLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
